Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

2013350 citationsJournal Articlebronze Open Access

Authors

Jerry S. Powell · University of California, Davis

John Pasi · Queen Mary University of London

Margaret V. Ragni · Hemophilia Center of Western Pennsylvania

Margareth C. Ozelo · Universidade Estadual de Campinas (UNICAMP)

Leonard A. Valentino · Rush University Medical Center

Johnny Mahlangu · University of the Witwatersrand

Neil C. Josephson

Abstract

Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B. (Funded by Biogen Idec; ClinicalTrials.gov number, NCT01027364.).

Topics & Keywords

Hemophilia Treatment and Research Cancer-related gene regulation Blood Coagulation and Thrombosis Mechanisms

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 24, pp. 2313-2323

DOI: 10.1056/nejmoa1305074

Field-Weighted Citation Impact: 21.57

Command Palette

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

Authors

Abstract

Topics & Keywords

Publication Details